MOONLAKE IMMUNO (MLTX)
(Real Time Quote from BATS)
$50.50 USD
-0.54 (-1.06%)
Updated Sep 13, 2024 12:48 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for MoonLake Immunotherapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -44.08 | -64.51 | -4.54 | -0.09 | NA |
Depreciation/Amortization & Depletion | 0.01 | 0.01 | 0.00 | 0.00 | NA |
Net Change from Assets/Liabilities | -6.22 | -1.43 | 3.96 | -0.22 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 7.51 | 10.03 | -0.03 | -0.01 | NA |
Net Cash From Operating Activities | -42.78 | -55.89 | -0.61 | -0.32 | NA |
Property & Equipment | -0.28 | -0.02 | 0.00 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | -24.90 | -32.32 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | -115.00 | NA |
Net Cash from Investing Activities | -25.18 | -32.34 | 0.00 | -115.00 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 482.45 | 0.00 | 0.00 | 112.70 | NA |
Issuance (Repayment) of Debt | 0.00 | -15.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | -0.06 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -2.75 | 134.69 | 0.00 | 3.95 | NA |
Net Cash from Financing Activities | 479.70 | 119.69 | -0.06 | 116.65 | NA |
Effect of Exchange Rate Changes | -0.08 | 0.01 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | 411.66 | 31.47 | -0.67 | 1.34 | NA |
Cash at Beginning of Period | 39.51 | 8.04 | 1.34 | 0.00 | NA |
Cash at End of Period | 451.17 | 39.51 | 0.67 | 1.34 | NA |
Diluted Net EPS | -0.73 | -1.70 | -0.31 | -0.04 | NA |
Fiscal Year End for MoonLake Immunotherapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -38.73 | -13.98 | -44.08 | -36.19 | -24.57 |
Depreciation/Amortization & Depletion | 0.05 | 0.02 | 0.01 | 0.01 | 0.01 |
Net Change from Assets/Liabilities | -8.17 | -2.84 | -6.22 | 0.32 | -0.69 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.01 | 1.85 | 7.51 | 5.43 | 4.07 |
Net Cash From Operating Activities | -42.84 | -14.95 | -42.78 | -30.43 | -21.18 |
Property & Equipment | -0.21 | -0.21 | -0.28 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -116.34 | -28.59 | -24.90 | -142.05 | 32.32 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -116.55 | -28.80 | -25.18 | -142.05 | 32.32 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 52.54 | 52.54 | 482.45 | 451.29 | 451.29 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.56 | -1.56 | -2.75 | 0.00 | 0.00 |
Net Cash from Financing Activities | 50.98 | 50.98 | 479.70 | 451.29 | 451.29 |
Effect of Exchange Rate Changes | 0.03 | 0.05 | -0.08 | -0.14 | -0.15 |
Net Change In Cash & Equivalents | -108.38 | 7.27 | 411.66 | 278.66 | 462.28 |
Cash at Beginning of Period | 451.17 | 451.17 | 39.51 | 39.51 | 39.51 |
Cash at End of Period | 342.79 | 458.44 | 451.17 | 318.17 | 501.79 |
Diluted Net EPS | -0.39 | -0.22 | -0.09 | -0.18 | -0.23 |